SCIEX Presents Novel QTOF Mass Spectrometry System for Simpler and Faster Biotherapeutics Characterisation
SCIEX focuses on reproducible data and education for biologics labs with the X500B QTOF at World ADC Summit
In the midst of increasing regulatory requirements for biotherapeutics development and manufacturing, scientists are continually looking for ways to improve the quality, reliability and reproducibility of characterisation data. The X500B QTOF System was specifically developed to deliver ease-of-use for high resolution standardised workflows for biotherapeutic developers, who are required to fully characterise biologic products in large numbers during the development process. The compact and user-friendly system includes powerful BioPharmaViewTM 2.0 processing software that simplifies complex data processing, resulting in faster generation of meaningful information. The software can also be used to interpret SWATH® 2.0 data independent acquisition on the X500B QTOF System. SWATH Acquisition allows comprehensive peptide mapping data to be acquired for every peptide in the sample from a single injection, including important low-abundance peptides and post-translational modifications that may be missed with other approaches.
Other innovative SCIEX solutions for biologics were featured at the World ADC Summit, including the PA 800 Plus Pharmaceutical Analysis System that provides automated quantitative analysis of biotherapeutics for development and quality control processes. The capillary electrophoresis system is proven within the industry to provide robust QA/QC for many capillary electrophoresis applications including characterisation of product purity, charge heterogeneity and glycan analysis. Glycan analysis has recently been enhanced with the launch of the Fast Glycan Labeling and Analysis Kit, which can run glycans up to five times faster than traditional HILIC approaches.
During the event, SCIEX presented a seminar entitled ‘The simpler and faster LC-MS solution for routine biopharmaceutical characterisation’ that focused on ADC development. The seminar – which was filled to capacity – gave new insights into improving ADC characterisation. Topics included ways to improve data quality while also simplifying data collection, and recent technology developments that have made mass spectrometry more accessible to routine biotherapeutics analysis.
SCIEX also held a workshop during the event, which included a presentation from Professor Yannis Francois on CESI-MS characterisation of ADCs. In this presentation Prof. Francois highlighted the use of the CESI 8000 Plus System for high-order structural interrogation of antibody-drug conjugates by a combination of intact, middle-up and bottom-up techniques using CESI-MS.
Learn more about the X500B from SCIEX at sciex.com/X500B and sciex.com/OS
AB SCIEX Germany GmbH
SCIEX helps to improve the world we live in by enabling scientists and laboratory analysts to find answers to the complex analytical challenges they face. The company's global leadership and world-class service and support in the capillary electrophoresis and liquid chromatography-mass spectrometry industry have made it a trusted partner to thousands of the scientists and lab analysts worldwide who are focused on basic research, drug discovery and development, food and environmental testing, forensics and clinical research.
With over 40 years of proven innovation, SCIEX excels by listening to and understanding the ever-evolving needs of its customers to develop reliable, sensitive and intuitive solutions that continue to redefine what is achievable in routine and complex analysis. For more information, please visit sciex.com.